Skip to main content
Premium Trial:

Request an Annual Quote

Canine Genetics Firm Embark Veterinary Raises $75M in Series B Round

NEW YORK — Embark Veterinary, which sells consumer DNA tests for dogs, said on Monday that it has raised $75 million in Series B funding.

The round was led by SoftBank Vision Fund 2 and included participation from previous investors F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital, and Third Kind Venture Capital.

Embark's test analyzes 200,000 genetic markers to provide owners and breeders with information about their dogs' breed, ancestry, health, and disease risk. The Boston-based company, which raised $10 million in a Series A round in early 2019, said it will use the new funding to accelerate the development of its discovery engine to expand its canine genetics database.

Competitors to Embark include Mars Petcare's Wisdom Health, OptiGen, and Paw Print Genetics.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.